Mr. Shane Madden reports

HYDREIGHT TECHNOLOGIES EXPANDS TELEHEALTH OFFERINGS WITH LAUNCH OF NAD+ THERAPY ON VSDHONE PLATFORM

Hydreight Technologies Inc. has expanded its VSDHOne platform with the launch of nicotinamide adenine dinucleotide (NAD+) therapy in three new delivery formats: patch, injection and nasal spray. This development further strengthens Hydreight's commitment to providing innovative and accessible wellness solutions through its national telehealth network. This launch positions Hydreight to capitalize on the rapidly expanding anti-aging and longevity market.

What is NAD+?

Nicotinamide adenine dinucleotide is a co-enzyme essential for metabolism, found in all living cells. It plays a critical role in energy production, cellular repair and DNA maintenance. As a co-enzyme in redox reactions, NAD+ helps convert nutrients into energy, making it central to mitochondrial function and overall cellular health.

NAD as an injectable has been around for a while, but bringing it to patients homes and expanding for those who do not like giving themselves injections to the additional dosage forms allow VSDHOne to serve a broader population. The nasal spray is more immediate delivery, as well, and the IonToPatch delivery is focused to carry the NAD to the area the patch is applied.

The growing anti-aging and longevity market

The global anti-aging market is experiencing significant growth, driven by increasing consumer demand for products and treatments that promote longevity and mitigate the effects of aging. In 2024, the market was valued at approximately $73-billion and is projected to reach around $140.94-billion by 2034 (Precedence Research). This growth is attributed to advancements in biotechnology, rising consumer awareness about longevity solutions and a growing aging population seeking to maintain optimal health. Hydreight's expansion into NAD+ therapy aligns with this trend, positioning the company at the forefront of science-backed longevity treatments.

Benefits of NAD+ therapy

NAD+ supplementation is widely used for its potential anti-aging, cognitive and metabolic benefits, including:

• Improved cognitive function and neuroprotection;
• Enhanced energy levels and mitochondrial support;
• Potential weight management benefits;
• Reduction in pain and inflammation, promoting overall well-being;
• Support for ATP production, the body's primary energy source;
• Improved athletic performance and reduced fatigue;
• Cholesterol management, mood regulation and blood pressure control;
• Potential neuroprotective effects in managing neurodegenerative diseases;
• Liver detoxification and reversal of alcohol-induced oxidative stress.

Mechanism of action

NAD+ functions as a co-enzyme within oxidoreductases, playing a crucial role in numerous biochemical processes that impact overall health and longevity. By supporting energy metabolism and DNA repair, NAD+ therapy can provide a broad range of physiological benefits.

NAD+ therapy now available on VSDHOne in three delivery formats

Hydreight's VSDHOne platform now offers three convenient administration routes for NAD+ therapy, providing flexibility for patients to choose the option that best fits their lifestyle:

1. NAD+ injection (IM/SQ) -- self-administered intramuscular or subcutaneous injection, allowing for direct absorption and rapid bioavailability;
2. NAD+ intranasal spray -- a daily-administered nasal spray offering a convenient and effective way to increase NAD+ levels;
3. NAD+ IonToPatch -- utilizing iontophoresis, a non-invasive transdermal drug delivery system that uses a voltage gradient to increase skin permeability, allowing for effective NAD+ absorption; the latex-free patch features a four-hour wear time and is designed for patients with active lifestyles.

Expanding access to innovative wellness solutions

The addition of NAD+ therapy to VSDHOne aligns with Hydreight's vision of making advanced wellness treatments more accessible through its nationwide network of health care providers. The VSDHOne platform streamlines the prescription, consultation and delivery process, ensuring that patients can receive high-quality, science-backed treatments conveniently and safely.

The NAD+ therapy options will be available to all VSDHOne customers, ensuring widespread access to these innovative wellness treatments.

"NAD+ therapy has gained significant attention for its role in cellular health and longevity," said Shane Madden, chief executive officer of Hydreight. "By integrating NAD+ into our VSDHOne platform, we are making it easier for patients to access this powerful co-enzyme in multiple convenient formats, ensuring they can benefit from its potential impact on energy, cognition and overall wellness."

About Hydreight Technologies Inc.

Hydreight is building one of the largest mobile clinic network in the United States. Its proprietary, fully integrated platform hosts a network of over 2,500 nurses, over 100 doctors and a pharmacy network across 50 states. The platform includes a built-in, easy-to-use suite of fully integrated tools for accounting, documentation, sales, inventory, booking and managing patient data, which enables licensed health care professionals to provide services directly to patients at home, office or hotel. Hydreight is bridging the gap between provider compliance and patient convenience, empowering nurses, medspa technicians and other licensed health care professionals. The Hydreight platform allows health care professionals to deliver services independently, on their own terms or to add mobile services to existing location-based operations. Hydreight has a 503-billion pharmacy network, servicing all 50 states, and is closely affiliated with a U.S. certified e-script and telemedicine provider network.

We seek Safe Harbor.